Zydus Lifesciences has secured final US FDA approval for its Ascorbic Acid Injection, a generic version of the treatment for scurvy. The product will be manufactured in Gujarat and marketed in the US.

  • Zydus Lifesciences received final US FDA approval for Ascorbic Acid Injection USP.
  • The product is a generic version of the reference drug 'Ascor Injection'.
  • The US FDA has designated the application as a Competitive Generic Therapy (CGT).
  • Manufacturing will take place at the Zydus plant in Jarod, near Vadodara, India.

In a significant boost to its international portfolio, Zydus Lifesciences has announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Ascorbic Acid Injection USP. The product is designed for the short-term treatment of scurvy, a condition resulting from vitamin C deficiency.

The approved injection will be available in multiple strengths, including 25,000 mg/50 mL and 5,000 mg/10 mL (500 mg/mL). Notably, the US FDA has designated this ANDA as a Competitive Generic Therapy (CGT). This designation is crucial as it may allow Zydus to benefit from a period of exclusivity, providing a strategic advantage in the highly competitive US generic market.

Read Also:RBI Proposes New Rules for Floating Rate Loans: Major Overhaul of Interest Rate and EMI Framework

Why This Matters

BozokMedia analysis shows that this approval underscores Zydus's ability to navigate complex regulatory landscapes to secure high-value generic products. By obtaining the CGT designation, Zydus is positioning itself to capture a significant share of a market where the reference listed drug had annual sales of approximately $11.6 million. This move strengthens the company's presence in the specialized injectable segment.

The CGT designation is a game-changer, offering Zydus a protected window to establish market dominance before broader competition enters.

The manufacturing process for this life-saving injection will be centralized at the group’s state-of-the-art injectable manufacturing facility located in Jarod, near Vadodara, Gujarat. Once produced, the product will be distributed and marketed across the United States by Zydus Pharmaceuticals (USA) Inc.

This development comes at a time when Zydus is aggressively expanding its global footprint, including its recent move to acquire the U.S. oncology firm Assertio for $166 million, signaling a robust growth trajectory in the pharmaceutical sector.

Historical Background

Scurvy has historically been one of the most devastating nutritional deficiency diseases, famously impacting sailors during long voyages. While now easily treatable with Ascorbic Acid (Vitamin C), the demand for high-quality, reliable generic injectable versions remains a vital component of global healthcare infrastructure, ensuring affordability and availability.

Did You Know?: The term 'scurvy' comes from the Old Norse word 'skyrbúi', referring to the debilitating effects of the disease on the body.

Frequently Asked Questions

1. What is the primary use of Ascorbic Acid Injection?
It is used for the short-term treatment of scurvy, which is caused by a lack of Vitamin C.

2. Where will this product be manufactured?
It will be manufactured at Zydus's injectable plant in Jarod, near Vadodara, India.